Resumo
Definição
History and exam
Key diagnostic factors
- presença de fatores de risco
- massa pélvica
- ascite
- derrame pleural
Other diagnostic factors
- sintomas gastrointestinais
- urgência urinária e polaciúria
- duração dos sintomas >3 meses
- distensão abdominal
- dor ou pressão pélvica/abdominal
Risk factors
- mutações genéticas associadas com o câncer de ovário hereditário
- idade mais avançada
- história familiar de câncer de ovário, câncer de mama, câncer colorretal e/ou câncer de endométrio
- nunca usou contraceptivos orais combinados
- nuliparidade
- obesidade
- terapia hormonal
- endometriose
Diagnostic investigations
1st investigations to order
- ultrassonografia pélvica
- CA-125
- histopatologia
Investigations to consider
- teste genético
- PET, PET-CT ou PET/RNM
- RNM
- Tomografia computadorizada (TC)
- testes de biomarcadores
Treatment algorithm
candidato à cirurgia, doença confirmada por histologia intraoperatória
não candidato à cirurgia, doença confirmada por biópsia
doença recorrente sensível à platina
doença resistente à platina recorrente ou refratária
Contributors
Authors
Sareena Singh, MD
Gynecologic Oncologist
Aultman Medical Group
Northeast Ohio Medical University
Canton
OH
Disclosures
SS declares that she has no competing interests.
Acknowledgements
Dr Sareena Singh would like to gratefully acknowledge Dr Justin C. Chura and Dr Allison E. Axtell, previous contributors to this topic.
Disclosures
JCC and AEA declare that they have no competing interests.
Peer reviewers
Michael P. Hopkins, MD, MEd
Chairman
Obstetrics and Gynecology
Northeast Ohio Universities of Medicine (NEOMED)
Rootstown
OH
Disclosures
MPH declares that he has no competing interests.
Ritu Salani, MD
Gynecologic Oncology Fellow
Johns Hopkins Medical Institutions
Baltimore
MD
Disclosures
RS declares that she has no competing interests.
Susan A. Davidson, MD
Associate Professor
Chief, Gynecologic Oncology
Department of Obstetrics & Gynecology (UCD)
University of Colorado Cancer Center
Aurora
CO
Disclosures
SAD declares that she has no competing interests.
Khadra Galaal, MBChB, MPH, MRCOG
Consultant Gynaecological Oncologist
Northern Gynaecological Oncology Centre
Queen Elizabeth Hospital
Gateshead
UK
Disclosures
KG is co-author of a systematic review of follow-up strategies after primary treatment in ovarian cancer. This is not referenced in this topic.
Jill Tseng, MD
Assistant Clinical Professor of Gynecologic Oncology
University of California, Irvine
Orange
CA
Disclosures
JT declares that she has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer [internet publication].Full text
González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Oct;34(10):833-48.Full text Abstract
Gaillard S, Lacchetti C, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update. J Clin Oncol. 2025 Mar;43(7):868-91.Full text Abstract
Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):61-85.Full text Abstract
Tew WP, Lacchetti C, Kohn EC, et al. Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022 Nov 20;40(33):3878-81.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Síndrome do intestino irritável (SII)
- Metástases no ovário
- Endometriose
More DifferentialsGuidelines
- Suspected cancer: recognition and referral
- Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update
More GuidelinesPatient information
Câncer de ovário: quais tratamentos funcionam?
Câncer de ovário: o que é?
More Patient informationLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer